AAKA

Aakaar Medical Technologies Stock Price

Symbol: NSEI:AAKAARMarket Cap: ₹1.2bCategory: Household

AAKAAR Share Price Performance

AAKAAR Community Fair Values

    Recent AAKAAR News & Updates

    No updates

    Aakaar Medical Technologies Ltd. Key Details

    ₹615.8m

    Revenue

    ₹262.2m

    Cost of Revenue

    ₹353.6m

    Gross Profit

    ₹293.2m

    Other Expenses

    ₹60.4m

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    4.26
    Gross Margin
    57.42%
    Net Profit Margin
    9.81%
    Debt/Equity Ratio
    98.0%

    Aakaar Medical Technologies Ltd. Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About AAKAAR

    Founded
    2013
    Employees
    177
    CEO
    Rahul Sawakhande
    WebsiteView website
    www.aakaarmedical.in

    Aakaar Medical Technologies Ltd. provides medical aesthetics and cosmetic dermatology treatment services. Its products include hair and skin care, injectables and contouring, and aesthetic devices. The company serves primarily to dermatologists, plastic surgeons, aesthetic physicians, and cosmetologists. Additionally, it also distributes products and devices from Korea, Spain, Italy, and Austria. The company was incorporated in 2013 and is based in Mumbai, India.

    Indian Market Performance

    • 7 Days: -1.8%
    • 3 Months: 5.5%
    • 1 Year: -6.0%
    • Year to Date: -0.3%
    Over the last 7 days, the market has dropped 1.8%, driven by a pullback of 2.7% in the Financials sector. In the last 12 months the market is down 6.0%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading